Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02197130 · ClinicalTrials.gov registry record · Phase 2
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
A Phase 2 study of Huntington's Disease, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 272
- Enrollment target
- 20
- Study locations
NCT02197130 is a Phase 2 study of Huntington's Disease that has completed, run by Pfizer. The registered enrollment target is 272 participants, below the 4,760-participant average among 8 other Huntington's Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02197130, a Phase 2 study of Huntington's Disease, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 272 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study. Primary endpoint is the change from baseline in the Total Motor Score (TMS) assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 26 weeks of treatment. secondary endpoints will include change from baseline in the Total Maximum Chorea (TMC) score of the UHDRS after 13 and 26 weeks of treatment and Clinical Global Impression-Improvement score after 13 and 26 weeks of treatment.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PF-02545920
Study Locations (20)
California
- University of California, Irvine - Irvine
- Ronald Regan UCLA Medical Center Drug Information Center - Los Angeles
- UCLA Neurology Clinic - Los Angeles
- UCLA Radiology - Los Angeles
Ohio
- Cleveland Clinic Foundation Hospital Pharmacy - Cleveland
- The Cleveland Clinic Foundation - Cleveland
- Davis Medical Center - Columbus
- The Wexner Medical Center at the Ohio State University - Columbus
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
- The University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Arizona - Phoenix
- Mayo Clinic Arizona - Scottsdale
Colorado
- Rocky Mountain Movement Disorders Center - Englewood
Florida
- University of Florida Center for Movement Disorders and Neurorestoration - Gainesville
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Massachusetts
- Massachusetts General Hospital - Charlestown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02197130
The ClinicalTrials.gov registry entry for NCT02197130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,760-participant average among 8 other Huntington's Disease trials with a reported enrollment target (94% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Huntington's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02197130 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT02197130 about?
NCT02197130 is a clinical study titled "Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease". This study is a 26 week, randomized, parallel group, double blind comparison of PF-02545920 5 mg, PF-02545920 20 mg, and placebo dosed BID in the treatment of motor impairment of subjects with Huntington's Disease. A total of approximately 260 subjects are planned to be randomized in the study. Prim...
What is the current status of trial NCT02197130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 272 participants. The study started on 2014-09. Estimated completion is 2016-10.
What conditions does trial NCT02197130 study?
This clinical trial studies the following conditions: Huntington's Disease.
What interventions are being tested in trial NCT02197130?
The interventions under investigation include: Placebo (OTHER), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT02197130?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02197130 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
RECRUITING
-
Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease
RECRUITING
-
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
RECRUITING
-
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
COMPLETED · Phase 1
-
FuRST 2.0 Cognitive Pre-Testing
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.